Relationship between effect of lamivudine in the treatment of cirrhotic patients with uncompensated hepatitis B with HBV genotypes and cytotoxic T lymphocyte.
- Author:
Dong WANG
1
;
Xi-Bing GU
1
;
Yin-Fang ZHU
1
;
Yang XIAO-JUAN
1
;
Xiang-Hu JIANG
1
;
Li-Hua HUANG
1
;
Yuan-Wang QIU
1
;
Hang-Yuan WU
1
;
Ping YU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Alanine Transaminase; metabolism; Antiviral Agents; therapeutic use; Female; Genotype; Hepatitis B; drug therapy; enzymology; immunology; virology; Hepatitis B virus; drug effects; genetics; isolation & purification; Humans; Lamivudine; therapeutic use; Liver Cirrhosis; drug therapy; enzymology; immunology; virology; Male; Middle Aged; T-Lymphocytes, Cytotoxic; immunology
- From: Chinese Journal of Experimental and Clinical Virology 2013;27(4):283-285
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore relationship between effect of Lamivudine in the treatment of cirrhotic patients with uncompensated hepatitis B with hepatitis B virus (HBV)genotypes and HBV specific cytotoxic T lymphocytes (CTL).
METHODS80 cases of uncompensated cirrhotic hepatitis B (40 cases with genotype B and 40 with genotype C), HBV DNA positive, HBeAg positive and human leukocyte antigen (HLA)-A2 positive,were treated with Lamivudine 100 mg/d, one year later, its effect and relationship with HBV genotypes and HBV specific CTL were observed.
RESULTSHBV DNA turned negative:40 cases with genotype B turned negative (100%). In the 9th and 10th month of treatment, there was one case with genotype C had YMDD variation respectively and Adefovir dipivoxil was used for treatment, of the rest 38 cases, HBV DNA of 26 cases (68.42%) turned negative,HBV DNA negative rate of patients with genotype is lower than that of patients with genotype B, chi2 = 14.91, P < 0.01. HBeAg turned negative: 18 cases with genotype B (45%) turned negative, more than that of patients with genotype C (7 cases, 18.42%), chi2 = 6.32, P < 0.05. Peripheral blood HBV specific CTL level: before treatment, it was (0.33 +/- 0.03)% of patients with genotype B,higher than that of patients with genotype C [(0.11 +/- 0.02)%], t = 8.12, P < 0.001. 1 year after treatment: it was (0.44 +/- 0.04)% of patients with genotype B, higher than that before treatment, t = 4.01, P < 0.001, it was also higher than that of patients with genotype C 1 year after treatment [(0.23 +/- 0.03)%], t = 5.63, P < 0.01, alanine amino-transferase (ALT) returned to normal: 38 cases with genotype B (95%) returned to normal, more than that of patients with genotype C (28 cases, 73.68%), X2 = 6.79, P < 0.01.
CONCLUSIONEffect of Lamivudinein the treatment of cirrhotic patients with uncompensated hepatitis B is better in patients with genotype B than patients with genotype C, its mechanism may be related to lower level of HBV specific CTL in patients with genotype C than patients with genotype B.
